PT-141 (bremelanotide) activates melanocortin-4 receptors in the central nervous system, modulating sexual desire and arousal independent of genital blood flow pathways. Subcutaneous bremelanotide is FDA-approved as Vyleesi for acquired HSDD in premenopausal women.
Compounded PT-141 strips and troches extend the mechanism to men and alternative delivery formats in telehealth sexual health. Onset is typically 45 to 60 minutes; effects last hours. Nausea is common (40% in trials); transient blood pressure increase requires caution in cardiovascular disease.
Not for daily use; on-demand dosing before sexual activity. CLYR Health offers PT-141 strips as a preview sexual health SKU alongside live PT-141 + oxytocin ODT products.